Patricia Andrews
Director/Board Member at GLYCOMIMETICS, INC.
Net worth: 223 524 $ as of 2024-03-30
Profile
Patricia S.
Andrews is currently the Chief Executive Officer & Global Head-Oncology at Sumitomo Dainippon Pharma Oncology, Inc. She is also a Director at Oncolytics Biotech, Inc. and an Independent Director at GlycoMimetics, Inc. Previously, she served as the Chief Executive Officer & Head-Oncology at Sumitomo Pharma Oncology, Inc. from 2017 to 2023.
She was also the Global Head-Oncology at Sumitomo Pharma Co., Ltd.
She worked as the Chief Commercial Officer & Executive VP at Incyte Corp.
from 2009 to 2012 and as the Vice President-Specialty Markets & General Manager at Pfizer Inc. in 2008.
Additionally, she held the position of Chief Commercial Officer & Executive VP at Boston Biomedical, Inc. from 2013 to 2017.
Prior to that, she was a Vice President-Capital Finance at HSBC Bank USA, NA in 1990.
Ms. Andrews received her undergraduate degree from Brown University and holds an MBA from the University of Michigan.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GLYCOMIMETICS, INC.
0.09% | 2024-03-14 | 58,608 ( 0.09% ) | 175 824 $ | 2024-03-30 |
ONCOLYTICS BIOTECH INC.
0.06% | 2024-03-06 | 45,000 ( 0.06% ) | 47 700 $ | 2024-03-30 |
Patricia Andrews active positions
| Companies | Position | Start |
|---|---|---|
| GLYCOMIMETICS, INC. | Director/Board Member | 2017-06-11 |
| ONCOLYTICS BIOTECH INC. | Director/Board Member | 2024-01-08 |
Sumitomo Dainippon Pharma Oncology, Inc.
 Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The private company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Chief Executive Officer | 2013-10-31 |
Former positions of Patricia Andrews
| Companies | Position | End |
|---|---|---|
| SUMITOMO PHARMA ONCOLOGY, INC. | Chief Executive Officer | 2022-12-31 |
| INCYTE CORPORATION | Corporate Officer/Principal | 2012-08-28 |
| PFIZER, INC. | Corporate Officer/Principal | 2008-09-30 |
HSBC Bank USA, NA
 HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Corporate Officer/Principal | 1989-12-31 |
| SUMITOMO PHARMA CO., LTD. | Corporate Officer/Principal | - |
Training of Patricia Andrews
| Brown University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| SUMITOMO PHARMA CO., LTD. | Health Technology |
| INCYTE CORPORATION | Health Technology |
| PFIZER, INC. | Health Technology |
| ONCOLYTICS BIOTECH INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The private company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
HSBC Bank USA, NA
HSBC Bank USA, NA Investment ManagersFinance HSBC Bank USA NA engages in the provision of banking services. Its lines of business are Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Private Bank. The company is headquartered in McLean, VA. | Finance |
Sumitomo Dainippon Pharma Oncology, Inc.
Sumitomo Dainippon Pharma Oncology, Inc. BiotechnologyHealth Technology Part of Sumitomo Chemical Co., Ltd., Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics. The private company is based in Cambridge, MA. The company has teams in the US and Japan and is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer. Sumitomo Dainippon Pharma Oncology is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. The company has a diverse and purposeful pipeline of targeted therapies. The CEO of the company is Patricia S. Andrews. | Health Technology |
| SUMITOMO PHARMA ONCOLOGY, INC. |
- Stock Market
- Insiders
- Patricia Andrews
